Citation: | HAN Zhigang, YU Tingting, SHEN Hongli, Alimjan Saitiwaerdi. Study on the correlation of Napsin-A expression and EGFR genes in non-small cell lung cancer tissue[J]. Journal of Clinical Medicine in Practice, 2014, (13): 1-3. DOI: 10.7619/jcmp.201413001 |
Yamashita Y, Nagasaka T, Naiki-Ito A. Napsin A is a specific marker for ovarian clear cell adenocarcinoma [J]. Modern Pathology, 2014.
|
Aulakh K S, Chisholm C D, Smith D A. TTF-1 and napsin A do not differentiate metastatic lung adenocarcinomas from primary esophageal adenocarcinomas:proposal of a novel staining panel [J]. ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, 2013(8):1094.
|
Oh M J, Choi J H, Kim I H. Detection of epidermal growth f actor receptor in the serum of patients with cervical carcinoma [J]. Clinical Cancer Research, 2000, (12):4760.
|
李连弟, 鲁凤珠, 张思维. 中国恶性肿瘤死亡率 20 年变化趋势和近期预测分析 [J]. 中华肿瘤杂志, 1997(1):3.
|
Turner B M, Cagle P T, Sainz I M. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma:evalua-tion of 1674 cases by tissue microarray [J]. ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, 2012(2):163.
|
Schauer-Vukasinovic V, Langen H, Giller T. Detection of im-munoreactive napsin A in human urine [J]. Biochimica et Biophysica Acta, 2001(1):51.
|
Lim S H, Lee J Y, Sun J M. Comparison of clinical out-comes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21 [J]. JOURNAL OF THORACIC ONCOLOGY, 2014(4):506.
|
Hwang K E, Kwon S J, Kim Y S. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790Mmutation of EGFR [J]. Experimental Cell Research, 2014(2):288.
|